Published in Leukemia on January 01, 1995
Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways. J Cell Biol (1997) 1.06
miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol (2012) 0.98
Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci U S A (1996) 0.90
Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells. Br J Cancer (2003) 0.88
Apoptosis of hepatoma cells SMMC-7721 induced by Ginkgo biloba seed polysaccharide. World J Gastroenterol (2002) 0.83
Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol (2014) 0.81
Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer (1998) 0.80
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin Hematol (2015) 0.80
Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukemia. Mol Med (1998) 0.78
New insights into the synergism of nucleoside analogs with radiotherapy. Radiat Oncol (2013) 0.78
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia (2016) 0.75
Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. Br J Cancer (1999) 0.75
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget (2016) 0.75
Novel rapid tissue lysis method to evaluate cancer proteins: correlation between elevated Bcl-X(L) expression and colorectal cancer cell proliferation. World J Gastroenterol (2005) 0.75
Periodic segregation of solute atoms in fully coherent twin boundaries. Science (2013) 1.70
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
The presence and expression of the hepatitis B virus in human oocytes and embryos. Hum Reprod (2011) 1.44
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant (2008) 1.08
Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol (1989) 1.08
Observation of a charged charmoniumlike structure in e+ e- → π+ π- J/ψ at sqrt[s] = 4.26 GeV. Phys Rev Lett (2013) 1.05
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol (2003) 1.05
Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J (2001) 1.04
Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia (2001) 1.03
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia (2009) 1.01
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A. Bone Marrow Transplant (1992) 1.01
Functional hyposplenism following allogeneic bone marrow transplantation. J Clin Pathol (1995) 0.99
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms. Br J Rheumatol (1988) 0.98
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia (2006) 0.98
Bone marrow transplantation: current situation, complications and prevention. J Antimicrob Chemother (1995) 0.97
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. Leukemia (2005) 0.97
ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation. Oncogene (2009) 0.95
Semi-automated brain tumor and edema segmentation using MRI. Eur J Radiol (2005) 0.95
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant (2011) 0.94
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol (2004) 0.94
Synthesis and antimalarial activity of artemisinin derivatives containing an amino group. J Med Chem (2000) 0.93
Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol (1998) 0.89
Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia. Hematol J (2001) 0.89
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol (1997) 0.89
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant (2001) 0.89
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer (1994) 0.88
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 0.88
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant (1993) 0.87
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia (2010) 0.87
Report on Shanghai norms for the Chinese translation of the Wechsler Intelligence Scale for Children-Revised. Psychol Rep (1990) 0.87
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy (2001) 0.86
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia. Clin Lab Haematol (1990) 0.86
First observation of the M1 transition ψ(3686)→γη(c)(2S). Phys Rev Lett (2012) 0.86
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant (1995) 0.86
Interactive volume cutting of medical data. Comput Biol Med (2006) 0.85
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course. Br J Haematol (1998) 0.85
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity. Br J Haematol (1979) 0.85
Cobalamin and folate binding proteins in human tumour tissue. J Clin Pathol (1984) 0.85
Observation of two new N* resonances in the decay ψ(3686)→ppπ0. Phys Rev Lett (2013) 0.85
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia (1999) 0.84
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant (2000) 0.84
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant (2007) 0.84
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant (1997) 0.84
A method of radio-frequency inhomogeneity correction for brain tissue segmentation in MRI. Comput Med Imaging Graph (2001) 0.84
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia (2003) 0.84
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol (1994) 0.84
Genomic selection of seed weight based on low-density SCAR markers in soybean. Genet Mol Res (2013) 0.84
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy (2000) 0.83
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia (1997) 0.83
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol (1994) 0.82
Heterogeneous mechanisms of autocrine growth of AML blasts. Br J Haematol (1989) 0.82
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol (1996) 0.82
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia (2012) 0.82
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol (2000) 0.82
A pyramidal approach for automatic segmentation of multiple sclerosis lesions in brain MRI. Comput Med Imaging Graph (1999) 0.82
Automated segmentation of multiple sclerosis lesions in multispectral MR imaging using fuzzy clustering. Comput Biol Med (2000) 0.81
Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients. J Hosp Infect (2002) 0.81
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol (2005) 0.81
Denoising human cardiac diffusion tensor magnetic resonance images using sparse representation combined with segmentation. Phys Med Biol (2009) 0.81
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry (1999) 0.81
Effect of erythropoietin in patients with myeloma. BMJ (1990) 0.81
Outcome of TiNi stent treatments in symptomatic central airway stenoses caused by Aspergillus fumigatus infections after lung transplantation. Transplant Proc (2013) 0.80
Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant (2003) 0.80
DNA repair mechanisms and acute myeloblastic leukemia. Hematol Oncol (2000) 0.80
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol (1992) 0.80
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol (1997) 0.79
Extrapolation method to obtain a full projection from a limited one for limited-view tomography problems. Med Biol Eng Comput (1993) 0.79
Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol (2000) 0.79
Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation. Clin Lab Haematol (1992) 0.79
Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia (1994) 0.79
[Effect of Leontopodium leontopodioides (Willd.) Beauv. on inflammation induced by animal reversed passive arthus (RPA)]. Zhongguo Zhong Yao Za Zhi (1994) 0.79
Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells. Br J Haematol (1995) 0.79
Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. J Immunol (1999) 0.79
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk Lymphoma (1997) 0.79
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res (2007) 0.78
A hybrid region-boundary model for cerebral cortical segmentation in MRI. Comput Med Imaging Graph (2006) 0.78
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Bone Marrow Transplant (2009) 0.78
Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia. Lancet (1981) 0.78
Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer (1990) 0.78
Real-time visualization of large volume datasets on standard PC hardware. Comput Methods Programs Biomed (2008) 0.78
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol (1996) 0.78